NUK - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov NUK. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 246
1.
  • Abiraterone acetate for tre... Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
    Fizazi, Karim, Prof Dr; Scher, Howard I, Prof; Molina, Arturo, MD ... The lancet oncology, 10/2012, Letnik: 13, Številka: 10
    Journal Article
    Recenzirano
    Odprti dostop

    Summary Background Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled ...
Celotno besedilo
2.
  • Abiraterone acetate plus pr... Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
    Ryan, Charles J, Prof; Smith, Matthew R, Prof; Fizazi, Karim, Prof ... The lancet oncology, 02/2015, Letnik: 16, Številka: 2
    Journal Article
    Recenzirano
    Odprti dostop

    Summary Background Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive ...
Celotno besedilo
3.
  • Cabazitaxel plus carboplati... Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial
    Corn, Paul G, MD; Heath, Elisabeth I, Prof; Zurita, Amado, MD ... The lancet oncology, 10/2019, Letnik: 20, Številka: 10
    Journal Article
    Recenzirano
    Odprti dostop

    SummaryBackgroundTaxane–platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials. Distinct ...
Celotno besedilo

PDF
4.
  • Effect of abiraterone aceta... Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial
    Logothetis, Christopher J, Prof; Basch, Ethan, MD; Molina, Arturo, MD ... The lancet oncology, 12/2012, Letnik: 13, Številka: 12
    Journal Article
    Recenzirano

    Summary Background Bone metastases are a major cause of morbidity in metastatic castration-resistant prostate cancer. Abiraterone acetate potently disrupts intracrine androgen receptor signalling ...
Celotno besedilo
5.
  • Personalised chemotherapy b... Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial
    Fizazi, Karim, Prof; Pagliaro, Lance, Prof; Laplanche, Agnes, MD ... The lancet oncology, 12/2014, Letnik: 15, Številka: 13
    Journal Article
    Recenzirano
    Odprti dostop

    Summary Background Poor prognosis germ-cell tumours are only cured in about half of patients. We aimed to assess whether treatment intensification based on an early tumour marker decline will improve ...
Celotno besedilo

PDF
6.
  • Docetaxel and dasatinib or ... Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
    Araujo, John C, Dr; Trudel, Géralyn C, PhD; Saad, Fred, Prof ... The lancet oncology, 12/2013, Letnik: 14, Številka: 13
    Journal Article
    Recenzirano
    Odprti dostop

    Summary Background Src kinase-mediated interactions between prostate cancer cells and osteoclasts might promote bone metastasis. Dasatinib inhibits tyrosine kinases, including Src kinases. Data ...
Celotno besedilo

PDF
7.
  • Abiraterone acetate plus pr... Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
    Basch, Ethan, Dr; Autio, Karen, MD; Ryan, Charles J, MD ... The lancet oncology, 11/2013, Letnik: 14, Številka: 12
    Journal Article
    Recenzirano

    Summary Background Abiraterone acetate plus prednisone significantly improves radiographic progression-free survival in asymptomatic or mildly symptomatic, chemotherapy-naive patients with metastatic ...
Celotno besedilo
8.
  • A Probabilistic Threshold-B... A Probabilistic Threshold-Based Bandwidth Sharing Policy for Wireless Multirate Loss Networks
    Moscholios, I. D.; Vassilakis, V. G.; Logothetis, M. D. ... IEEE wireless communications letters, 06/2016, Letnik: 5, Številka: 3
    Journal Article
    Recenzirano

    We propose a probabilistic bandwidth sharing policy, based on the threshold (TH) policy, for a single cell of fixed capacity in a homogeneous wireless cellular network. The cell accommodates random ...
Celotno besedilo

PDF
9.
  • Addition of estramustine to... Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data
    Fizazi, Karim, Dr; Le Maitre, Aurelie, MSc; Hudes, Gary, MD ... The lancet oncology, 11/2007, Letnik: 8, Številka: 11
    Journal Article
    Recenzirano

    Summary Background Estramustine phosphate is a mustard-oestradiol conjugate, and has hormonal and non-hormonal effects. In phase II trials of patients with cancer, response to microtubule inhibitors ...
Celotno besedilo
10.
  • PSA response to neoadjuvant... PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era
    McGuire, Sean E; Lee, Andrew K; Cerne, Jasmina Z ... International journal of radiation oncology, biology, physics, 01/2013, Letnik: 85, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    The aim of the study was to evaluate the prognostic value of prostate-specific antigen (PSA) response to neoadjuvant androgen deprivation therapy (ADT) prior to dose-escalated radiation therapy (RT) ...
Celotno besedilo

PDF
1 2 3 4 5
zadetkov: 246

Nalaganje filtrov